Ajanta Pharma gets 2 procedural observation from USFDA for Dahej unit
12th Sep 2022

United States Food and Drug Administration (USFDA) has issued Form 483 with 2 procedural observations to Ajanta Pharma’s formulation facility at Dahej in Gujarat. USFDA has conducted inspection at Dahej unit from September 05, 2022 to September 09, 2022. The company is in the process of responding to the same within the stipulated time prescribed by USFDA.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.